RU2010115407A - MATRIX TABLET WITH THE BASIS FOR THE LONG-TERM RELEASE OF TRIMETAZIDINE AND THE METHOD OF ITS PRODUCTION - Google Patents
MATRIX TABLET WITH THE BASIS FOR THE LONG-TERM RELEASE OF TRIMETAZIDINE AND THE METHOD OF ITS PRODUCTION Download PDFInfo
- Publication number
- RU2010115407A RU2010115407A RU2010115407/15A RU2010115407A RU2010115407A RU 2010115407 A RU2010115407 A RU 2010115407A RU 2010115407/15 A RU2010115407/15 A RU 2010115407/15A RU 2010115407 A RU2010115407 A RU 2010115407A RU 2010115407 A RU2010115407 A RU 2010115407A
- Authority
- RU
- Russia
- Prior art keywords
- matrix tablet
- tablet according
- trimetazidine
- core
- matrix
- Prior art date
Links
- 239000013563 matrix tablet Substances 0.000 title claims abstract 19
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 title claims abstract 9
- 229960001177 trimetazidine Drugs 0.000 title claims abstract 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract 5
- 230000007774 longterm Effects 0.000 title 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 7
- 229960003943 hypromellose Drugs 0.000 claims abstract 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000000945 filler Substances 0.000 claims abstract 4
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 238000013268 sustained release Methods 0.000 claims abstract 4
- 239000012730 sustained-release form Substances 0.000 claims abstract 4
- 239000004408 titanium dioxide Substances 0.000 claims abstract 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000003831 antifriction material Substances 0.000 claims abstract 2
- 239000001913 cellulose Substances 0.000 claims abstract 2
- 229920002678 cellulose Polymers 0.000 claims abstract 2
- 235000010980 cellulose Nutrition 0.000 claims abstract 2
- 238000007907 direct compression Methods 0.000 claims abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 229910052710 silicon Inorganic materials 0.000 claims abstract 2
- 239000010703 silicon Substances 0.000 claims abstract 2
- 239000000377 silicon dioxide Substances 0.000 claims abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229960005196 titanium dioxide Drugs 0.000 claims 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Матричная таблетка с основой для пролонгированного высвобождения триметазидина, состоящая из ядра, содержащего в качестве действующего вещества триметадизидин или его фармацевтически приемлемые соли и вспомогательные вещества, а также растворяющуюся оболочку, отличающаяся тем, что ядро содержит 8-12% триметазидина или его фармацевтически приемлемой соли. ! 2. Матричная таблетка по п.1, отличающаяся тем, что в качестве матрицеобразующего компонента ядро содержит 20,0-50,0% гипромеллозы. ! 3.Матричная таблетка по п.1, отличающаяся тем, что в качестве наполнителя ядро содержит 33,38-68,18% целлюлозы микрокристаллической или иного наполнителя, способствующего получению ядра прямым прессованием. ! 4. Матричная таблетка по п.1, отличающаяся тем, что в качестве антифрикционного вещества ядро содержит 0,5-1,0% магния стеарата. ! 5. Матричная таблетка по п.1, отличающаяся тем, что в качестве вещества, способствующего текучести, ядро содержит 0,2-0,5% кремния диоксида коллоидного. ! 6. Матричная таблетка по п.1, отличающаяся тем, что оболочка содержит 1,25-2,50% гипромеллозы. ! 7. Матричная таблетка по п.1, отличающаяся тем, что оболочка содержит 0,16-0,63% Макрогол 4000 (ПЭГ). ! 8. Матричная таблетка по п.1, отличающаяся тем, что оболочка содержит 0,63-0,94% титана диоксида. ! 9. Способ изготовления матричной таблетки с основой для пролонгированного высвобождения триметазидина по любому из пп.1-8, отличающийся тем, что смешивают триметазидин гидрохлорид и кремний диоксид коллоидный и калибруют, далее полученную смесь смешивают с гипромеллозой и целлюлозой микрокристаллической и опудривают магния стеаратом, затем опудренную смесь прессуют с последующим нанес 1. A matrix tablet with a base for the sustained release of trimetazidine, consisting of a core containing trimethadisidine or its pharmaceutically acceptable salts and excipients as an active ingredient, as well as a dissolving shell, characterized in that the core contains 8-12% trimetazidine or its pharmaceutically acceptable salt. ! 2. The matrix tablet according to claim 1, characterized in that, as a matrix-forming component, the core contains 20.0-50.0% hypromellose. ! 3. The matrix tablet according to claim 1, characterized in that the core contains 33.38-68.18% microcrystalline cellulose or other filler as a filler, which facilitates the production of a core by direct compression. ! 4. The matrix tablet according to claim 1, characterized in that the core contains 0.5-1.0% magnesium stearate as an antifriction substance. ! 5. The matrix tablet according to claim 1, characterized in that, as a substance that promotes fluidity, the core contains 0.2-0.5% silicon colloidal dioxide. ! 6. The matrix tablet according to claim 1, characterized in that the shell contains 1.25-2.50% hypromellose. ! 7. The matrix tablet according to claim 1, characterized in that the shell contains 0.16-0.63% Macrogol 4000 (PEG). ! 8. The matrix tablet according to claim 1, characterized in that the shell contains 0.63-0.94% titanium dioxide. ! 9. A method of manufacturing a matrix tablet with a basis for the sustained release of trimetazidine according to any one of claims 1 to 8, characterized in that trimetazidine hydrochloride and silicon dioxide are mixed and calibrated, then the resulting mixture is mixed with microcrystalline hypromellose and cellulose and then magnesium stearate is dusted, then the powdered mixture is pressed followed by
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010115407/15A RU2445958C2 (en) | 2010-04-20 | 2010-04-20 | Matrix tablet with trimetazidine prolonged-release base and method for preparing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010115407/15A RU2445958C2 (en) | 2010-04-20 | 2010-04-20 | Matrix tablet with trimetazidine prolonged-release base and method for preparing it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010115407A true RU2010115407A (en) | 2011-10-27 |
| RU2445958C2 RU2445958C2 (en) | 2012-03-27 |
Family
ID=44997726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010115407/15A RU2445958C2 (en) | 2010-04-20 | 2010-04-20 | Matrix tablet with trimetazidine prolonged-release base and method for preparing it |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2445958C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116008440A (en) * | 2023-02-21 | 2023-04-25 | 山东省食品药品检验研究院 | Method for determining metabolic regulator trimetazidine in livestock and poultry meat and aquatic products by mixed mode solid phase extraction-HPLC-MS/MS |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2530558C2 (en) * | 2012-04-26 | 2014-10-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Method of obtaining medical form of trimetazidine of prolonged action |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802424B1 (en) * | 1999-12-17 | 2002-02-15 | Adir | MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION |
| UA12297U (en) * | 2005-11-24 | 2006-01-16 | Pharma Start Ltd Liability Com | Matrix tablet providing for delayed release of trimetasin |
| EA009810B1 (en) * | 2006-12-26 | 2008-04-28 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Matrix for manufacturing tableted dosage form and method of treatment |
| RU2362548C1 (en) * | 2007-11-20 | 2009-07-27 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Matrix tablet with basis for trimetazidine dihydrochloride release, way of its reception and way of treatment |
| UA45562U (en) * | 2009-07-15 | 2009-11-10 | Роман Николаевич Приходько | Dosage form of trimetasin dihydrochloride in form of delayed-release matrix tablet |
-
2010
- 2010-04-20 RU RU2010115407/15A patent/RU2445958C2/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116008440A (en) * | 2023-02-21 | 2023-04-25 | 山东省食品药品检验研究院 | Method for determining metabolic regulator trimetazidine in livestock and poultry meat and aquatic products by mixed mode solid phase extraction-HPLC-MS/MS |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2445958C2 (en) | 2012-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017088610A (en) | TABLET CONTAINING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR SALT THEREOF | |
| FI2498756T4 (en) | Tablet formulations of neratinib maleate | |
| RU2014145557A (en) | COMBINED COMPOSITION CONTAINING A MULTI-COMPONENT SPHEROIDAL TABLET (MKST) CONCLUDED IN A SOLID CAPSULE AND METHOD FOR PREPARING IT | |
| RU2011117177A (en) | DOSED MEDICINAL FORMS 3- (6- (1- (2,2-DIFLUORBENZO [d] [1,3] DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIDIN-2-IL) BENZOIC ACID | |
| JP2015523407A5 (en) | ||
| EA200702627A1 (en) | DOSED FORMS FOR ORAL APPLICATION, CONTAINING PROGESTERONS, AND METHODS OF THEIR MANUFACTURING AND USE | |
| RU2013125148A (en) | ORAL PHARMACEUTICAL TABLET WITH REGULATED MESALAZINE RELEASE AND METHOD FOR ITS PRODUCTION | |
| HRP20240564T1 (en) | Novel pharmaceutical composition | |
| JP2014534197A5 (en) | ||
| RU2016128216A (en) | FILMED TABLET CONTAINING ALPHOSCERATE CHOLINE AND METHOD FOR PRODUCING IT | |
| JP2016530238A5 (en) | ||
| RU2015138784A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF MULTIPARTICLES CONTAINING A LOT OF GRANULES OF TWO SPECIES | |
| RU2010115407A (en) | MATRIX TABLET WITH THE BASIS FOR THE LONG-TERM RELEASE OF TRIMETAZIDINE AND THE METHOD OF ITS PRODUCTION | |
| RU2013157528A (en) | DRY COATED TABLET CONTAINING TEGAFUR, HIMERACYL AND POTASSIUM OTERACIL | |
| RU2019105711A (en) | PHARMACEUTICAL COMPOSITION CONTAINING POMALIDOMIDE | |
| JP2015129124A5 (en) | ||
| WO2013098268A3 (en) | Tablets and dry-coated agents | |
| RU2012121183A (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| WO2014006635A3 (en) | Solid oral compositions of silodosin | |
| RU2013126056A (en) | COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) | |
| MX2015015681A (en) | Pharmaceutical composition comprising fingolimod. | |
| RU2015101769A (en) | COMBINED DRUG LERCANIDIPINE AND ATORVASTATIN | |
| RU2018128416A (en) | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION INCLUDING A QUINOLINE DERIVATIVE OR ITS SALT | |
| RU2013107724A (en) | PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST AND LEVOCETIRISINE | |
| JP2014070061A5 (en) |